Board meeting on 19 Oct 2026 to approve Q2 and H1 FY27 results

Revenue growth above 20%Profit growth above 25%Negative operating cash flowResults View source PDF Explain this filing

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.1%Reaction day

₹1810.10

prior close

₹1868.90

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%+3.3% vs market

Specialty Chemicals peers, median of 102sector+0.4%+3.7% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 3.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.4

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.1+0.8+3.3+0.4+3.7

Next day

+2.1+1.0+1.1+0.6+1.5

+6.9+1.7+5.2+1.6+5.3

+7.2+0.1+7.1+0.2+7.0

+7.5+0.8+6.7+0.9+6.6

+5.8-0.9+6.7-0.5+6.3

-9.1-4.5-4.6-4.6-4.5

15d

-9.6-4.8-4.8-5.9-3.7

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 102Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tatva Chintan Pharma Chem informed BSE and NSE that its Board will meet on 19 October 2026 to consider, approve and take on record the standalone and consolidated unaudited financial results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026). The trading window for designated persons is closed from 1 October 2026 till 48 hours after the results are made public.

Likely market impact

Routine pre-results intimation. Watch for Q2 and H1 FY27 earnings on 19 October; expect stock movement around the announcement.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹217.3 Cr	₹123.5 Cr	+75.9%
Operating profit	₹27.19 Cr	₹12.66 Cr	+114.8%
Profit after tax	₹21.45 Cr	₹9.92 Cr	+116.3%
EBITDA margin	18.7%	18.0%	+0.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.